Archive for September, 2009|Monthly archive page
BIOLOGY, CELL, heal, medicine, muscle, REPAIR, san fran, skele, STEM
In VICTORIES & SUCCESS STORIES on September 30, 2009 at 4:03 pm
“Our study shows that the ability of old human muscle to be maintained and repaired by muscle stem cells can be restored to youthful vigor”
Clues To Reversing Aging Of Human Muscle Discovered
ScienceDaily (Sep. 30, 2009) — A study led by researchers at the University of California, Berkeley, has identified critical biochemical pathways linked to the aging of human muscle. By manipulating these pathways, the researchers were able to turn back the clock on old human muscle, restoring its ability to repair and rebuild itself.
The findings will be reported in the Sept. 30 issue of the journal EMBO Molecular Medicine, a peer-reviewed, scientific publication of the European Molecular Biology Organization.
“Our study shows that the ability of old human muscle to be maintained and repaired by muscle stem cells can be restored to youthful vigor given the right mix of biochemical signals,” said Professor Irina Conboy, a faculty member in the graduate bioengineering program that is run jointly by UC Berkeley and UC San Francisco, and head of the research team conducting the study. “This provides promising new targets for forestalling the debilitating muscle atrophy that accompanies aging, and perhaps other tissue degenerative disorders as well.”
via Clues To Reversing Aging Of Human Muscle Discovered.
Like this:
Be the first to like this post.
breast cancer awareness, breats, cancer, DISEASE, eli, growth hormone, lilly, milk, pill, rbgh
In ALL ARTICLES on September 29, 2009 at 11:57 pm
Eli Lilly is now the sole manufacturer of rBGH — the artificial growth hormone given to dairy cows that increases people’s risk of cancer. Eli Lilly also manufactures breast cancer treatment medications and a pill that “reduces the risk” of breast cancer. Eli Lilly is milking cancer. Tell them to stop making rBGH.
Like this:
Be the first to like this post.
actc, ALXN, AOLS, ARIA, ASTM, BHRT, bmsn, BTIM, ccel, CELG, cris, cur, DNDN, GERN, IART, INCR, ISCO, KOOL, MCET, MEDS, OCHT, OSIR, OSTE, PKI, PPMD, PSTI, SPPI, STEM, stock, VODG
In BUSINESS OF STEM CELLS on September 29, 2009 at 12:32 pm
WHAT ARE ALL OF THE STEM CELL STOCKS DOING?
To see a REAL TIME list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS – REAL TIME
To see a DAY WATCH list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS - DAY WATCH
To see a BASIC list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS - BASIC
To see a SUMMARRY list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS - SUMMARRY
These are the stocks currently covered:
ACTC.PK ALXN AOLS.OB ARIA ASTM BHRT BMSN.OB BTIM.OB CCEL.OB CELG CRIS CUR DNDN GERN IART INCR.OB ISCO.OB KOOL MCET.OB MEDS.PK OCHT.PK OSTE OSIR PKI PPMD.PK PSTI SPPI STEM VODG.OB
Changes to this list may occur without notice. Information provided by YAHOO FINANCE is for information and educational purposes only. All stock prices and trades should be verified b a certified broker.
thanks to the The Stem Cell Stock List.
Like this:
Be the first to like this post.
In ALL ARTICLES on September 29, 2009 at 12:18 am
Stem cell hope for childhood motor neuron disease
* 22:00 22 September 2009 by Andy Coghlan
A form of motor neuron disease that affects children has been treated in mice with injections of stem cells into the spinal cord. The treatment extended the lives of the mice beyond and kept them more mobile, giving hope that similar approaches might help people.
The treated mice were bred to have a form of motor neuron disease called spinal muscular atrophy with respiratory distress type 1, or SMARD 1, which affects 1 or 2 in every 100,000 children.
Diaphragms of infant children with the disease stop working, so they need mechanical ventilators to stay alive. Nerves in muscles of the extremities are also affected, gradually limiting movement of hands and feet.
“At present there is no cure for this disorder, besides ventilation and prevention of infections,” says Giacomo Comi of the University of Milan, Italy, who led the research…
via Stem cell hope for childhood motor neuron disease – health – 22 September 2009 – New Scientist.
Like this:
Be the first to like this post.
carell, debate, stem cell, stewart
In ALL ARTICLES on September 28, 2009 at 11:42 pm
Stem Cell Debate – 2001 – A blast from the past
Steve Carell would rather debate over Dutch prostitutes than stem cell research.
Stem Cell Therapy For Heart Failure – The most amazing videos are a click away
Like this:
Be the first to like this post.
ADULT, cancer, CELL, embryo, hodkins, lymph, STEM, TREAT
In SCIENCE & STEM CELLS on September 28, 2009 at 11:01 pm
Browse > Home / Hodgkin’s Lymphoma, News, Progressive Relapsed Hodgkin’s Lymphoma / Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma
Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma
September 24, 2009
Children and adolescents with relapsed Hodgkin’s lymphoma respond well to allogeneic stem cell transplantation, according to the results of a study published in Blood.[1]
Although children and adolescents with Hodgkin’s lymphoma have an excellent prognosis, some do relapse. These patients may benefit from stem cell transplantation, which involves the delivery of high doses of chemotherapy, followed by the infusion of stem cells, which serve to “rescue” bone marrow and hasten blood cell production and immune system recovery. Autologous stem cell transplants involve the patient’s own stem cells, whereas allogeneic stem cell transplants require the collection of donor stem cells.
Allogeneic stem cell transplantation has not been widely used in children and adolescents with Hodgkin’s lymphoma because of a high rate of nonrelapse mortality (NRM), which is mainly caused by acute and/or chronic graft-versus-host disease (GVHD); GVHD occurs when the patient’s body rejects the donor cells. Researchers from the European Group for Blood and Marrow Transplantation conducted a study that involved 91 children age 18 or younger with relapsed or refractory Hodgkin’s lymphoma who were treated with an allogeneic stem cell transplant between 1987 and 2005. Fifty-one patients received reduced intensity conditioning (RIC) (lower doses of chemotherapy), and 40 patients received myeloablative conditioning (MAC) (higher doses of chemotherapy). (Of the 40 patients who had failed a prior autologous transplant, 32 received RIC.) The results of the study indicated the following:
- Non-relapse mortality at one year was 21%, with similar results for RIC or MAC.
- The two-year relapse rate was 36%.
- The five-year relapse rate was 44%.
- There were more relapses in the RIC group than the MAC group.
- Progression-free survival was 40%.
- Overall survival was 54%.
The researchers concluded that allogeneic stem cell transplantation “is a viable treatment strategy for children and adolescents with relapsed Hodgkin’s lymphoma who failed most if not all other options available.” Reference: [1] Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin’s lymphoma: An analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009; 114: 2060-2067.
via Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma | CancerConsultants.
Like this:
Be the first to like this post.
als, alzheimer's, DIABETES, international, leukemia, MS, parkinson's, SCII, seaway, spinal, stem cell, swvl, therapy
In BUSINESS OF STEM CELLS on September 28, 2009 at 9:50 pm
STEM CELL THERAPY INTERNATIONAL (OTCBB: SCII)
“Up 41.54% on Friday”
Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It provides allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer’s Disease, Parkinson’s Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company’s stem cell biological solutions can be used to alleviate the side effects of chemotherapy. Its principal stem cell products are solutions containing allo stem cell biological solutions, either adult stem cells, and stem cells that are extracted from umbilical cord blood. It intends to offer biological solutions containing stem cell products primarily in the United States to universities, institutes, and privately funded laboratory facilities for research purposes and clinical trials. The company was incorporated in 2004 and is headquartered in Tampa, Florida.
About OTCPicks.com
Like this:
Be the first to like this post.
biotech, BONE, cd34, clinical, lymph, MARROW, stem cell, taigen, trial
In BUSINESS OF STEM CELLS on September 28, 2009 at 9:21 pm
Excellent SC Mobilization + Safety Profile for TG-0054
TAIPEI, Taiwan, Sept. 28 /PRNewswire-Asia/ — TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated.
The trial was a randomized, double-blind, placebo-controlled, single intravenous dose study including 64 healthy volunteers in US, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG-0054 in 8 cohorts. The mobilized stem and progenitor cells peaked at 4-6 hours following one single intravenous dose.
“We are greatly encouraged by the phase 1 study results which indicates that TG-0054 has the potential to be used alone, not in combination with G- CSF, for allogenic or autologous stem cell transplantation in cancer patients. This should greatly reduce the hospital and other associated cost for such a procedure. Importantly, the activity and safety profile in the phase 1 study will support our future development of TG-0054 in chemosensitization and tissue ischemia, including myocardial infarction, stroke and severe intermittent claudication. Our preclinical animal disease models and the phase 1 study results lend strong support to clinical development for these clinical indications,” said Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen.
via Excellent Stem Cell Mobilization and Safety Profile for TG-0054.
Like this:
Be the first to like this post.
botkin, BUSH, ethics, medical, NIH, stem cell, UNIVERSITY, utah
In ALL ARTICLES on September 28, 2009 at 9:20 pm
U. expert to lead stem cell research panel
University of Utah medical ethics expert Jeffrey R. Botkin has been named chairman of a new nine-member group that will act as a clearinghouse for science research project requests for embryonic stem cells.
Requests for the cells are expected to increase significantly with the lifting of restrictions imposed by the Bush administration on National Institutes of Health research guidelines that all but prohibited embryonic stem cells to be used in scientific research.
via Deseret News | U. expert to lead stem cell research panel.
Like this:
Be the first to like this post.
bill, embryo, federal, funding, NIH, OBAMA, stem cell
In BUSINESS OF STEM CELLS on September 28, 2009 at 9:19 pm
NIH moves forward with expanded funding for stem cell research
September 21, 2009 | 12:25 pm
The National Institutes of Health moved closer today to fulfilling President Obama’s pledge to expand the number of stem cell lines eligible for use in federally funded research projects.
Dr. Francis Collins, the NIH’s new director, named members of a working group that will vet applications from researchers who want to add specific lines of human embryonic stem cells to the agency’s official stem cell registry. The group’s analysis will go to an NIH advisory committee, which will make recommendations to Collins, who will make the final decision about whether a particular cell line is acceptable.
To be eligible for federal funding, embryonic stem cell lines derived since July 9 – when the new rules went into effect – must meet strict ethical rules for embryo donation and informed consent. For instance, fertility clinic patients who are interested in donating their excess embryos to medical researchers must give their consent on two separate occasions. It must also be made explicit that their embryos will be destroyed if they are used to make stem cell lines.
via NIH moves forward with expanded funding for stem cell research | Booster Shots | Los Angeles Times.
Like this:
Be the first to like this post.
